Outpatient Use of Monoclonal Antibodies in Pregnant Individuals With Mild or Moderate Coronavirus Disease 2019 (COVID-19). Issue 1 (7th July 2022)

• Record Type: Journal Article
• Authors: Eid, Joe; Abdelwahab, Mahmoud; Williams, Hayley; Lehman, Joy; Malvestutto, Carlos; Landon, Mark B.; Costantine, Maged M.; Rood, Kara M.
• Is Part Of: Obstetrics and gynecology. Volume 140:Issue 1(2022)
• Page Start: 74
• Page End: 76
• Publication Date: 2022-07-07
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1097/AOG.0000000000004826
• Languages: English
• ISSNs: 0029-7844

Abstract

Abstract : Unvaccinated pregnant patients with mild or moderate coronavirus disease 2019 (COVID-19) who received outpatient monoclonal antibodies were less likely to be admitted to the hospital for worsening illness. Abstract : Treatment with monoclonal antibodies has been shown to significantly reduce the risk of hospitalization and disease progression among high-risk patients with coronavirus disease 2019 (COVID-19). Pregnant individuals were excluded from the original trials. In this single-center retrospective cohort study, we evaluated whether monoclonal antibody treatment in pregnant individuals is associated with decreased risk of hospitalization. Outcomes of patients who received the treatment were compared with those who were eligible but did not receive the treatment. Analyses were stratified by vaccination status. Unvaccinated pregnant patients with mild or moderate COVID-19 who received outpatient monoclonal antibodies were less likely to be admitted to the hospital (4.2% vs 15.7%, odds ratio 0.24, 95% CI 0.07–0.74), whereas among vaccinated patients, the treatment was not associated with a lower rate of hospitalization (2.3% vs 0%, P =.99).